Teflaro
Payments companies reported to CMS as associated with Teflaro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Teflaro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Teflaro
These are the largest totals companies reported as associated with Teflaro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| George Sakoulas | San Diego, CA | Infectious Disease | $229,936.45 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $76,733.02 |
| Frank Lovecchio | Phoenix, AZ | Internal Medicine | $35,473.17 |
| Javeed Siddiqui | Roseville, CA | Infectious Disease | $31,626.24 |
| Joshua Rosenberg | Brooklyn, NY | Critical Care Medicine (Internal Medicine) | $31,570.29 |
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $22,888.01 |
| Jose Vazquez | Augusta, GA | Infectious Disease | $21,483.63 |
| Michael Gelfand | Memphis, TN | Infectious Disease | $13,077.94 |
| Mark Pierce | Cookeville, TN | Infectious Disease | $12,861.35 |
| Chris Farnum | Lansing, MI | Infectious Disease | $10,279.08 |
Prescribed Teflaro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.